Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06106763
Other study ID # 23.05.2022-2022/05
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date September 24, 2022

Study information

Verified date October 2023
Source Istanbul Sabahattin Zaim University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research was conducted as an experimental research to determine the effect of mandala painting on pain, anxiety, depression and quality of life in patients undergoing hemodialysis.


Description:

The effect of mandala painting on pain, anxiety, depression and quality of life in patients undergoing hemodialysis.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date September 24, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: be over 18 Ability to communicate adequately Absence of psychiatric problems Volunteering to participate in the research Receiving hemodialysis treatment for at least 3 months Exclusion Criteria: None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mandala coloring
Mandala coloring page

Locations

Country Name City State
Turkey Istanbul Sabahattin Zaim University, Faculty of Health Sciences Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul Sabahattin Zaim University

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Choi H, Hahm SC, Jeon YH, Han JW, Kim SY, Woo JM. The Effects of Mindfulness-Based Mandala Coloring, Made in Nature, on Chronic Widespread Musculoskeletal Pain: Randomized Trial. Healthcare (Basel). 2021 May 28;9(6):642. doi: 10.3390/healthcare9060642. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analogue Scale (VAS) The patients were asked to mark their level of pain during relaxation or activities on a 10 cm vertical or horizontal line. In addition, there were forms which were numbered from 1-10 or from 1-100. The number 0 is found at the beginning of the line, and the number 10 is located at the end of the line. A value of 0 shows that there is no pain, and the value 10 expresses unendurable pain. GAS is a common scale in the assessment of pain level. A patient is asked to mark the perceived pain on this line, and the marked point is measured in cm 1. week
Primary Visual Analogue Scale (VAS) The patients were asked to mark their level of pain during relaxation or activities on a 10 cm vertical or horizontal line. In addition, there were forms which were numbered from 1-10 or from 1-100. The number 0 is found at the beginning of the line, and the number 10 is located at the end of the line. A value of 0 shows that there is no pain, and the value 10 expresses unendurable pain. GAS is a common scale in the assessment of pain level. A patient is asked to mark the perceived pain on this line, and the marked point is measured in cm 3. week
Primary Hospital Anxiety and Depression Scale (HAD) The scale was designed to screen anxiety and depression mood states in the population with physical illness in a short time. The HAD scale consists of 2 subscales and 14 items scored between 0-3 as a 4-point Likert-type scale. The anxiety subscale includes items 1, 3, 5, 7, 9, 11 and 13 and is scored between 0-21, the depression subscale includes items 2, 4, 6, 8, 10, 12 and 14 and is scored between 0-21. The scoring of items 1, 3, 5, 6, 8, 10, 11 and 13 is 3,2,1,0, while the scoring of items 2, 4, 7, 9, 12 and 14 is 0,1,2,3. A score above 7 in the depression subscale is compatible with depression, while a score above 10 in the anxiety subscale is compatible with anxiety. 1. week
Primary Hospital Anxiety and Depression Scale (HAD) The scale was designed to screen anxiety and depression mood states in the population with physical illness in a short time. The HAD scale consists of 2 subscales and 14 items scored between 0-3 as a 4-point Likert-type scale. The anxiety subscale includes items 1, 3, 5, 7, 9, 11 and 13 and is scored between 0-21, the depression subscale includes items 2, 4, 6, 8, 10, 12 and 14 and is scored between 0-21. The scoring of items 1, 3, 5, 6, 8, 10, 11 and 13 is 3,2,1,0, while the scoring of items 2, 4, 7, 9, 12 and 14 is 0,1,2,3. A score above 7 in the depression subscale is compatible with depression, while a score above 10 in the anxiety subscale is compatible with anxiety. 3. week
Primary Kidney Disease Quality of Life Form (KDQOL-36) The first part of the KDQOL-36 (items 1-12) includes the medical outcomes study short form 12 health survey (SF-12) as a generic core. It includes questions about general health, activity limits, ability to accomplish desired tasks, depression and anxiety, energy level, and social activities. These 12 items make up the physical component summary (PCS) and mental component summary (MCS) scales. Some items contribute most to the PCS scale (items 1-5 and 8), whereas other items contribute most to the MCS scale (items 6, 7, and 9-12). The second part (items 13-16) constitutes burden of kidney disease subscale. It includes questions about how much kidney disease interferes with daily life, takes up time, causes frustration, or makes the respondent feel like a burden. The third part (items 17-28) covers symptoms and problem list subscale. It includes questions about how bothered a respondent feels by sore muscles, chest pain, cramps, itchy or dry skin, shortness of breath, faintness, lack o 1. week
Primary Kidney Disease Quality of Life Form (KDQOL-36) The first part of the KDQOL-36 (items 1-12) includes the medical outcomes study short form 12 health survey (SF-12) as a generic core. It includes questions about general health, activity limits, ability to accomplish desired tasks, depression and anxiety, energy level, and social activities. These 12 items make up the physical component summary (PCS) and mental component summary (MCS) scales. Some items contribute most to the PCS scale (items 1-5 and 8), whereas other items contribute most to the MCS scale (items 6, 7, and 9-12). The second part (items 13-16) constitutes burden of kidney disease subscale. It includes questions about how much kidney disease interferes with daily life, takes up time, causes frustration, or makes the respondent feel like a burden. The third part (items 17-28) covers symptoms and problem list subscale. It includes questions about how bothered a respondent feels by sore muscles, chest pain, cramps, itchy or dry skin, shortness of breath, faintness, lack o 3. week
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06382701 - Effect of Aromatherapy on Pain, Anxiety and Satisfaction in Cannulation N/A
Completed NCT04674930 - Effects of Exercise Program on Physical Functioning of Hemodialysis Patients. N/A
Recruiting NCT02245633 - Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients N/A
Recruiting NCT01970280 - Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Phase 4
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Completed NCT05693584 - The Effect of Using Virtual Reality Glasses on Pain During Fistula Cannulation in Hemodialysis Patients N/A
Completed NCT01932853 - Association Between Dose Dialysis by Kt and Mortality N/A
Completed NCT01273974 - The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients Phase 2/Phase 3
Completed NCT04139759 - THE EFFECT OF HAND AND FOOT MASSAGE ON FATIGUE IN HEMODIALYSIS PATIENTS N/A
Not yet recruiting NCT05574595 - Effect on Pain and Comfort Associated With Fistula Puncture N/A
Completed NCT04175652 - Effects of Laughter Yoga on Hemodialysis Patients' Plasma-Beta Endorphin Levels, Pain Levels and Sleep Quality N/A
Not yet recruiting NCT06314243 - The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients Phase 3
Completed NCT01596842 - Effect of Omega-3 Fatty Acid on Vitamin D Activation Phase 4
Enrolling by invitation NCT01896882 - Dietary Sodium Restriction in Hemodialysis Patients N/A
Completed NCT00638300 - Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD) N/A
Terminated NCT00259714 - Dialysate Sodium Individualization in Hemodialysis Phase 1
Completed NCT01846754 - Prevalence of Fatigue in Hemodialysis Patients N/A
Completed NCT00491868 - Clinical Study of R744 to Hemodialysis Patients Phase 3
Not yet recruiting NCT06449105 - The Effect of Mindfulness Compassionate Living Practice on Hemodialysis Patients N/A
Completed NCT04195919 - The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients Phase 1